UPDATED: Expanding on injectable schizophrenia franchise, J&J secures nod for first twice-yearly treatment
Schizophrenia, like any psychiatric condition, can be notoriously difficult to treat. But J&J’s Janssen unit is championing a new approval in the indication Wednesday, one it says offers long-lasting effects.
The FDA has OK’ed a twice-yearly injectable treatment for schizophrenia, J&J announced Wednesday, an antipsychotic known as six-month paliperidone palmitate. J&J will market the drug as Invega Hafyera, marking the first approved schizophrenia therapy to be administered in half-year intervals.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.